Background: The platelet inhibitory response of clopidogrel is substantially variable among patients, and numerous studies have shown that post-percutaneous intervention, patients with high on-treatment platelet reactivity have an increase in risk of major adverse cardiovascular events. No published studies to date have utilized platelet function monitoring assays prior to coronary artery bypass graft (CABG) surgery, but determination of patients' antiplatelet effects prior to surgery may decrease time to surgery and length of hospital stay. The purpose of the study was to evaluate the clinical outcomes of non-elective CABG patients analyzed by the VerifyNow P2Y12 platelet-function monitoring assay prior to surgery compared to a similar set of patients not analyzed by the VerifyNow P2Y12 assay. Methods: This was a retrospective, single center, cohort study. The primary endpoints of this study were time to surgery and length of hospital stay. Results: From March 2013 to July 2013, 60 patient charts were reviewed and included in this study. 49 patients were analyzed by the VerfiyNow P2Y12 assay, and 16 of these patients underwent non-elective CABG surgery. Eleven patients underwent non-elective CABG surgery and were not analyzed by the VerifyNow P2Y12 assay. There was no difference between groups regarding time to surgery (p = 0.75) or length of stay (p = 0.42). Based on the assay's P2Y12 reaction unit results, 69% of VerifyNow P2Y12 patients went to surgery sooner than the institution's recommendations which generated more bleeding events, half of which were considered major bleeds. Conclusions: Utilization of the VerifyNow P2Y12 assay prior to non-elective CABG surgery does not shorten time to surgery or overall length of hospital stay. However, insufficient P2Y12 reaction units prior to surgery may lead to more bleeding events, thus the application of platelet function monitoring assays prior to procedures may be beneficial as a bleeding risk-assessment tool.
Introduction
Dual anti-platelet therapy is part of the standard of care provided to acute coronary syndrome (ACS) patients. The current ACCF/AHA/SCAI guidelines for percutaneous coronary intervention (PCI) recommend ACS patients undergoing PCI with stenting be administered a loading dose of a P2Y12 receptor inhibitor (either clopidogrel, prasugrel, or ticagrelor) followed by a lower, maintenance dose for at least twelve months [1] . In contrast, the ACCF/AHA guidelines for coronary artery bypass graft (CABG) surgery recommend patients referred for elective CABG discontinue clopidogrel and ticagrelor for at least 5 days prior to surgery and prasugrel for at least 7 days to limit bleeding complications. Patients referred for urgent CABG should discontinue clopidogrel and ticagrelor for at least 24 hours to reduce major bleeding complications [2] . Although the guidelines differ in the amount of antiplatelet activity needed, both emphasize the importance of maintaining hemostatic balance.
The platelet inhibitory response of clopidogrel is substantially variable among patients [3] - [6] . Additionally, numerous studies have shown that high on-treatment platelet reactivity with clopidogrel is associated with an increased risk of cardiovascular events (e.g. cardiovascular death, nonfatal myocardial infarction, stent thrombosis) after PCI [7] - [11] . Through these findings, platelet function monitoring assays have been developed to provide better risk stratification of patients and to help guide clinical decisions. Light transmittance aggregometry (LTA) with adenosine diphosphate (ADP) stimulation is the current gold standard assay; however, it is not suitable for routine clinical practice. LTA has proven to be time-consuming, requires intensive sample preparation by an experienced technician, and the results are not instantaneous [12] [13] . In lieu of these disadvantages, alternative platelet function assays have been developed to provide point-of-care testing. One such assay, VerifyNow P2Y12, has been developed and approved by the Food and Drug Administration (FDA) to specifically and rapidly monitor the inhibitory effects of thienopyridine-therapy. VerifyNow P2Y12 compares the platelet reactivity of the blood sample to the sample's baseline platelet function and reports results as BASE (an estimate of the patient's baseline platelet function independent of P2Y12 receptor inhibition), P2Y12 reaction units (PRU), and percent platelet inhibition [13] [14] . Several head-to-head comparisons between the VerifyNow P2Y12 assay and LTA have been completed with the majority of trials revealing significant correlation between the two methods of measurement [15] - [18] .
The current literature utilizes these antiplatelet assays post-PCI to determine potential drug efficacy by measuring the platelet inhibitor response in patients. According to the manufacturer, a PRU value less than or equal to 208 represents specific evidence for the presence of expected antiplatelet effect and is associated with reduced rates of thrombosis. Additionally, lower PRU values are associated with risk for bleeding, and measurements less than 95 are considered to be at highest risk for major bleeding [14] . When evaluating patients with high on-treatment platelet reactivity post-PCI, several studies have used PRU cutoffs of 230 or greater based on receiver-operating characteristic (ROC) curve analyses [19] - [23] . ROC curve analyses identify the level of ontreatment reactivity that provided the maximal sensitivity and specificity for the prediction of major adverse cardiovascular events after PCI [23] . Based on these interpretations, if these point-of-care assays were to be used prior to surgery, patients not exhibiting the desired antiplatelet effect would have higher than expected platelet aggregation and may be able to go to surgery sooner without increasing their risk for bleeding. With these presumptions, our institution implemented the utilization of the VerifyNow P2Y12 assay in 2009 as part of the cardiothoracic vascular surgery pre-operation protocol. The purpose of this retrospective study is to evaluate the clinical outcomes of non-elective CABG patients analyzed by the VerifyNow P2Y12 assay compared to similar patients who were not analyzed by the assay.
Methods
This study was designed as a retrospective, single-center, cohort study. The trial was conducted at a 433-bed tertiary care center that serves as a primary cardiac hospital in its community. Patients were included if they underwent non-elective CABG surgery between March 2013 and July 2013. Patients were excluded if they were less than 18 years old, were not on a P2Y12 inhibitor at home, or did not receive a dose of a P2Y12 inhibitor prior to surgery.
Eligible patients were separated into two groups: those who were analyzed by the VerifyNow P2Y12 assay and those who were not. A subpopulation of any patient who received the VerifyNow P2Y12 assay during the study period was also obtained in order to determine other clinical settings in which the assay was being utilized. The results of the VerifyNow P2Y12 assay were interpreted using the manufacturer and institution's recom-mendations. Post-procedure, a PRU < 208 was representative of the expected antiplatelet effect. Pre-procedure, a PRU > 250 was indicative of sufficient platelet aggregation to proceed with surgery.
The primary endpoints were time to surgery and length of hospital stay. Secondary endpoints included the clinical utility of the VerifyNow P2Y12 assay, changes in antiplatelet therapy post-surgery, composite and individual instance of all-cause death, myocardial infarction, stent thrombosis, stroke, and target vessel revascularization, and the rates of major and minor bleeding. Time to surgery was defined as time from admission to time of CABG surgery in hours. Length of hospital stay was defined as time from admission to hospital discharge. Bleeding events were defined by the thrombolysis in myocardial infarction (TIMI) bleeding criteria. Major bleeds included intracranial hemorrhage or a 5 gm/dL decrease in hemoglobin concentration or a 15% absolute decrease in the hematocrit. If CABG related, major bleeds included fatal bleeding, perioperative intracranial bleeding, transfusion of at least 5 units of whole blood, reoperation following closer of sternotomy incision for the purpose of controlling bleeding, receiving packed red blood cells within a 48 h period, and chest tube output > 2 L within a 24 h period. Minor bleeds were defined as any clinically overt sign of hemorrhage that is associated with a fall in hemoglobin of 3 to 5 gm/dL or a fall in hematocrit 9% to ≤15%.
Statistical Analysis
Data was analyzed using Microsoft Excel. Continuous data were analyzed using a log10-transformed student t-test to decrease the variance among data. Categorical data were analyzed using a Chi-square test or a Fischer's exact test if the sample size of any subgroup was less than or equal to five. All tests used a 95% confidence interval with an alpha less than or equal to 0.05.
Results
From March 2013 through July 2013, 60 patients were reviewed and included in the study. Forty-nine patients were analyzed by the VerifyNow P2Y12 assay. Sixteen of these 49 patients of these patients underwent nonelective CABG surgery and the remaining 33 patients underwent elective CABG surgery or other procedures. Eleven of the 60 patients underwent non-elective CABG surgery and were not analyzed by the VerifyNow P2Y12 assay and served as the control group (Figure 1) .
Among all 49 patients analyzed by the assay, 25 (51%) underwent CABG surgery with 16 (32.7%) being nonelective and 9 (18.4%) being elective. Other utilizations of the assay included 3 bronchoscopies (6.1%), 4 thoracotomies/thoracoscopies (8.2%), 3 endarterectomies (6.1%), 6 vascular procedures (12.2%), 6 left heart catheterizations/angiograms/PCI (12.2%), 3 heart valve repair/replacements (6.1%), and 5 other procedures (10.2%) ( Table 1 Baseline characteristics of non-elective CABG patients were similar among both study groups, with the only significant difference being more diabetic patients in the VerifyNow P2Y12 group. On average, patients were 60 years old with 50% -60% of the study population being male. More than 90% of patients were Caucasian with normal renal function. The average hemoglobin and hematocrit were 12 g/dL and 38% respectively, and the majority of patients also had coronary artery disease, hypertension, and dyslipidemia as comorbidities ( Table 2) .
Overall, there were no significant differences among the primary endpoints of this study. Time to surgery was very similar between the two groups with the mean time being 69.4 hr in the VerifyNow P2Y12 group and 79.4 h in the control group (p = 0.75). Patients who were analyzed by the VerifyNow P2Y12 assay had a shorter length of stay, 9.8 days, compared to the control group, 12.4 days, but this finding was not statistically significant (p = 0.42) ( Table 3) .
With regards to secondary endpoints, fewer percentage of patients who were analyzed by the VerifyNow P2Y12 assay had changes in antiplatelet therapy post-CABG surgery (10 out of 16 (62.5%) VerifyNow P2Y12 patients vs. 9 out of 11 (81.8%) control patients); however, this finding was not statistically significant (p = 0.2). In both groups, the most common change in antiplatelet therapy was not restarting the P2Y12 inhibitor post-CABG surgery. There were no incidences of death, myocardial infarction, stent thrombosis, stroke, and/or target vessel revascularization among the VerifyNow P2Y12 patients, and 1 case of stroke and 1 case of death among the control patients.
Non-elective CABG patients analyzed by the VerifyNow P2Y12 assay had more bleeding events (including individual major and minor bleeds) than those not analyzed by VerifyNow; however, none of these events were statistically significant ( Table 4) . When analyzing the PRU values of the non-elective CABG VerifyNow P2Y12 patients, only 5 out of 16 patients (31.3%) had a PRU > 250 per institution protocol. Twelve out of 16 patients (75%) had a bleeding event, and half of these were major bleeds. Of these major bleeds, all except one had a PRU < 250. Seven out of 16 patients received blood products (43.8%), and all had PRU values < 250 (Table 5).
Discussion
The current utility of platelet function monitoring assays is post-PCI to identify patients with high-on treatment platelet reactivity that are at an increased risk of major adverse cardiovascular events. Although no studies have used these assays prior to CABG surgery, determination of antiplatelet effects prior to surgery has the potential to decrease time to surgery for patients exhibiting decreased response to P2Y12 inhibitors. Additionally, if patients undergo CABG procedures sooner due to inadequate platelet inhibition, the overall length of hospital stay may be decreased without an increased risk of bleeding. This study did not find that the application of the VerifyNow P2Y12 assay impacted the time to surgery or length of hospital stay. This could have been due to the small sample size of both groups which restricts the ability to determine significant difference. In addition, starting the time to surgery from admission could have skewed the overall results because chart reviews revealed that numerous patients were originally admitted for non-cardiac reasons, and a subsequent heart catheterization performed later during the admission determined the need for urgent CABG surgery. It would have been more accurate to define time to surgery as time from heart catheterization to initiation of CABG surgery, but this data was not available for all patients included in this study.
The most common change in antiplatelet therapy post-CABG was discontinuation of the P2Y12 inhibitor. Since the current 2011 ACC/AHA practice guidelines for CABG do not recommend dual-antiplatelet therapy post-CABG, continuing aspirin only was in accordance with current practice [2] . This study did show that lower PRU values lead to more bleeding events despite no statistical significance. In addition, there were significantly more diabetic patients among those who received the VerifyNow P2Y12 assay; however, it is unlikely that this difference majorly impacted the overall results. Diabetes is not an independent risk factor for bleeding in hospitalized patients according to the 2012 Antithrombotic Therapy and Prevention of Thrombosis CHEST guidelines, and a significant difference may not be apparent in a larger patient population [24] . Although no clinical trials have assessed PRU values prior to surgery, the results of this study suggest that PRU values < 250 provide insufficient platelet aggregation and bleeding risks versus benefits should be evaluated prior to surgery. Despite the overall lack of statistical significance, this study shows the potential utilization of platelet-function monitoring assays prior to CABG surgery to help assess benefits versus risk of bleeding.
Conclusion
Utilization of the VerifyNow P2Y12 assay prior to non-elective CABG surgery does not shorten time to surgery or overall length of hospital stay. Despite these findings, application of platelet function monitoring assays prior to procedures may be beneficial at assessing patients' risk of bleeding since lower P2Y12 reaction units prior to surgery may lead to more bleeding events.
